PIK3CA mutation predicts resistance to anti-HER2 treatment and chemotherapy

Where to next for the elderly with acute myeloid leukaemia?

New line of therapy for acute myeloid leukaemia

Encouraging early results with GS-9973 for CLL and NHL

Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL)

Treating ALL patients with T cells targeted for CD19

Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL

Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies

T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence

Removal of alpha/beta T cells and of CD19 B cells in children With acute leukaemia

Transplantation and short telomeres increase the risk of cognitive impairment

Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy